iShares Biotechnology ETF
763 hedge funds and large institutions have $7.8B invested in iShares Biotechnology ETF in 2020 Q2 according to their latest regulatory filings, with 160 funds opening new positions, 257 increasing their positions, 198 reducing their positions, and 58 closing their positions.
New
Increased
Maintained
Reduced
Closed
Holders
763
Holders Change
+97
Holders Change %
+14.56%
% of All Funds
15.68%
Holding in Top 10
24
Holding in Top 10 Change
+10
Holding in Top 10 Change %
+71.43%
% of All Funds
0.49%
New
160
Increased
257
Reduced
198
Closed
58
Calls
$615M
Puts
$736M
Net Calls
-$121M
Net Calls Change
+$249M
Top Buyers
| 1 |
Goldman Sachs
New York
|
+$315M |
| 2 |
BNP Paribas Financial Markets
Paris,
France
|
+$253M |
| 3 |
JPMorgan Chase & Co
New York
|
+$217M |
| 4 |
CM
Churchill Management
Los Angeles,
California
|
+$213M |
| 5 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
+$85.2M |
Top Sellers
| 1 |
Bank of America
Charlotte,
North Carolina
|
-$169M |
| 2 |
Citigroup
New York
|
-$120M |
| 3 |
Barclays
London,
United Kingdom
|
-$63.1M |
| 4 |
Morgan Stanley
New York
|
-$47.8M |
| 5 |
Millennium Management
New York
|
-$31.9M |
